Table 4.
Leukocyte and lymphocyte counts in hepatitis C virus chronically infected patients treated with interferon-α plus ribavirin
| Groups | Control group | Group E6 | Group E9 | Group L6 | Group L9 | |
| Total number of patients | 30 | 16 | 16 | 15 | 15 | |
| Baseline leukocyte counts | mean ± SD | 6.7 ± 2.1 | 7.0 ± 1.5 | 7.7 ± 2.3 | 6.4 ± 2.0 | 7.0 ± 2.2 |
| (Min; Max) | (3.5; 12.1) | (4.2; 9.0) | (3.8; 12.2) | (4.0; 11.1) | (2.0; 10.5) | |
| Week 12 leukocyte counts | mean ± SD | 4.5 ± 1.5 | 4.4 ± 1.8 | 5.0 ± 1.5 | 3.7 ± 0.9 | 4.7 ± 0.9 |
| (Min; Max) | (2.3; 9.0) | (2.3; 8.4) | (3.1; 7.3) | (2.7; 5.1) | (3.4; 6.8) | |
| Week 48 leukocyte counts | mean ± SD | 4.3 ± 1.3 | 3.6 ± 1.2 | 4.4 ± 1.5 | 3.7 ± 1.3 | 4.9 ± 0.9 |
| (Min; Max) | (2.5; 7.6) | (1.6; 6.7) | (2.3; 7.6) | (2.5; 6.6) | (2.9; 5.8) | |
| Statistics (P value)1 | < 0.001 | 0.001 | < 0.001 | 0.001 | 0.013 | |
| Statistics (P value)2 | < 0.010 | 0.001 | 0.001 | 0.001 | 0.023 | |
| Baseline lymphocyte counts | mean ± SD | 37.8 ± 8.6 | 35.7 ± 7.6 | 33.7 ± 7.5 | 36.7 ± 10.7 | 37.6 ± 8.7 |
| (Min; Max) | (22.8; 58.8) | (21.8; 52.5) | (19.8; 53.8) | (18.3; 51.4) | (25.4; 50.7) | |
| Week 12 lymphocyte counts | mean ± SD | 38.2 ± 9.7 | 34.6 ± 6.9 | 30.5 ± 8.0 | 36.1 ± 9.5 | 36.5 ± 7.5 |
| (Min; Max) | (20.3; 52.9) | (22.0; 44.1) | (15.8; 47.4) | (22.5; 55.2) | (25.3; 52.0) | |
| Week 48 lymphocyte counts | mean ± SD | 32.0 ± 8.9 | 37.1 ± 8.3 | 31.2 ± 6.9 | 34.9 ± 11.3 | 33.1 ± 6.2 |
| (Min; Max) | (13.3; 57.8) | (19.5; 50.9) | (21.3; 45.0) | (19.8; 54.0) | (23.5; 42.3) | |
| Statistics (P value)1 | ns | ns | ns | ns | ns | |
| Statistics (P value)2 | 0.004 | ns | ns | ns | ns | |
1
Week 12 vs baseline in one group;
2
Week 48 vs baseline in one group (Differences were considered significant when P < 0.05; Wilcoxon signed ranks test for leukocyte counts, Paired t test for lymphocyte counts). Results are given as 109 cells/L in the case of leukocytes and as % in the case of lymphocytes. ns: Not significant.